Literature DB >> 9225971

Mutational analysis and expression studies of the neurofibromatosis type 2 (NF2) gene in a patient with a ring chromosome 22 and NF2.

H Kehrer-Sawatzki1, M Udart, W Krone, R Baden, R Fahsold, G Thomas, B Schmucker, G Assum.   

Abstract

The case of a seriously disabled and retarded female patient with neurofibromatosis type 2 (NF2) is reported. She suffered from bilateral vestibular schwannomas, multiple intracranial meningiomas and neurinomas. The constitutional karyotype of the patient was 46, XX, r(22)/45,XX,-22. A constitutional G to A transition in the proximal 3' untranslated region of isoforms 1 and 2 was identified in the patient's NF2 gene and shown not to affect differential splicing or mRNA stability. The instability of the ring chromosome 22 with the associated loss of tumor suppressor genes on chromosome 22, in particular the loss of the NF2 gene, are assumed to have caused multiple tumorigenesis in this patient.

Entities:  

Mesh:

Year:  1997        PMID: 9225971     DOI: 10.1007/s004390050467

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  3 in total

1.  Spinal neurofibromatosis without café-au-lait macules in two families with null mutations of the NF1 gene.

Authors:  D Kaufmann; R Müller; B Bartelt; M Wolf; K Kunzi-Rapp; C O Hanemann; R Fahsold; C Hein; W Vogel; G Assum
Journal:  Am J Hum Genet       Date:  2001-10-18       Impact factor: 11.025

2.  Neuropsychiatric decompensation in adolescents and adults with Phelan-McDermid syndrome: a systematic review of the literature.

Authors:  Alexander Kolevzon; Elsa Delaby; Elizabeth Berry-Kravis; Joseph D Buxbaum; Catalina Betancur
Journal:  Mol Autism       Date:  2019-12-24       Impact factor: 7.509

3.  Pathogenesis of vestibular schwannoma in ring chromosome 22.

Authors:  Ellen Denayer; Hilde Brems; Paul de Cock; Gareth D Evans; Frank Van Calenbergh; Naomi Bowers; Raf Sciot; Maria Debiec-Rychter; Joris V Vermeesch; Jean-Pierre Fryns; Eric Legius
Journal:  BMC Med Genet       Date:  2009-09-22       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.